A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatic Impairment (HI)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
Contact: Study coordinator (Edgewise Therapeutics, Inc.) · cardiacstudies@edgewisetx.com · 720-262-7002
Orlando Clinical Research Center, Orlando, Florida, United States
Contact: Study coordinator (Edgewise Therapeutics, Inc.) · cardiacstudies@edgewisetx.com · 720-262-7002

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Miami, United States · Orlando, United States

A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function

Healthy Adult Participants · Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Bengbu, China

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Hepatic Impairment · Moderate Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Orlando, United States · San Antonio, United States